[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse PPP1R1B

Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF05395 Protein phosphatase inhibitor 1/DARPP-32
Function

Inhibitor of protein-phosphatase 1.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0001975 response to amphetamine
GO:0006469 negative regulation of protein kinase activity
GO:0007611 learning or memory
GO:0007612 learning
GO:0007617 mating behavior
GO:0007618 mating
GO:0007621 negative regulation of female receptivity
GO:0007632 visual behavior
GO:0008306 associative learning
GO:0008542 visual learning
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0014075 response to amine
GO:0019098 reproductive behavior
GO:0033673 negative regulation of kinase activity
GO:0042326 negative regulation of phosphorylation
GO:0044708 single-organism behavior
GO:0045924 regulation of female receptivity
GO:0050890 cognition
GO:0051348 negative regulation of transferase activity
GO:0060180 female mating behavior
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0004862 cAMP-dependent protein kinase inhibitor activity
GO:0004864 protein phosphatase inhibitor activity
GO:0004865 protein serine/threonine phosphatase inhibitor activity
GO:0008599 protein phosphatase type 1 regulator activity
GO:0019207 kinase regulator activity
GO:0019208 phosphatase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019212 phosphatase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0019888 protein phosphatase regulator activity
GO:0030291 protein serine/threonine kinase inhibitor activity
GO:0031748 D1 dopamine receptor binding
GO:0031749 D2 dopamine receptor binding
GO:0031750 D3 dopamine receptor binding
GO:0031751 D4 dopamine receptor binding
GO:0031752 D5 dopamine receptor binding
GO:0050780 dopamine receptor binding
Cellular Component GO:0043025 neuronal cell body
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
hsa04728 Dopaminergic synapse
Reactome R-HSA-180024: DARPP-32 events
R-HSA-111885: Opioid Signalling
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPP1R1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPP1R1B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPP1R1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0710.891
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8580.308
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7550.292
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3650.619
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3840.803
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.350.834
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.2320.162
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7730.534
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.5170.266
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3340.626
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.90.332
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7780.0427
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPP1R1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP1R1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP1R1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP1R1B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP1R1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPP1R1B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPP1R1B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPP1R1B
Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B
Aliases DARPP-32; FLJ20940; dopamine and cAMP regulated phosphoprotein; DARPP32; dopamine and cAMP-regulated neurona ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPP1R1B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.